Key Highlights

Risk & Performance

Based on historical performance

High Risk

Score: 80/100

Failure Rate

40.0%

2 terminated/withdrawn out of 5 trials

Success Rate

60.0%

-26.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

100%

3 of 3 completed trials have results

Key Signals

3 with results

Phase 1

3(60.0%)

Phase 2

2(40.0%)

5Total

Phase 1(3)

Phase 2(2)

Loading network data...

Showing 5 of 5 trials

Safety, Tolerability and Efficacy Study of LiRIS® 400 mg in Women With Interstitial Cystitis

Role: collaborator

A Safety, Tolerability and Preliminary Efficacy Study of LiRIS® 400 mg in Women With Interstitial Cystitis (IC) and Hunner's Lesions

Role: collaborator

Double-Blind Placebo Controlled Study of Safety,Tolerability, and Efficacy of LiRIS® in Women With Interstitial Cystitis

Role: collaborator

Safety Study of LiRIS in Interstitial Cystitis (IC) Patients

Role: collaborator

Safety and Tolerability Study of the Taris Placebo System

Role: lead

All 5 trials loaded